Gao W Y, Han F S, Storm C, Egan W, Cheng Y C
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510.
Mol Pharmacol. 1992 Feb;41(2):223-9.
Phosphorothioate oligodeoxycytidine (S-dCn) was used as a model compound to examine the impact of the number of phosphorothioate linkages and their position on the inhibition of human DNA polymerases and RNase H in vitro. S-dCn with a chain length longer than 15 could inhibit human DNA polymerases and RNase H activities, in a linkage number-dependent manner. Longer oligomers were more potent inhibitors than shorter ones. Kinetic studies indicated that S-dC28 was a competitive inhibitor of DNA polymerase alpha and beta with respect to the DNA template, whereas it was a noncompetitive inhibitor of polymerases gamma and delta. S-dC28 was also a competitive inhibitor of RNase H1 and H2 with respect to RNA-DNA duplex. Susceptibility of these enzymes to inhibition by S-dC28 was in the order of delta approximately gamma greater than alpha greater than beta and RNase H1 greater than RNase H2. Structural-activity relationships were explored with a group of S-dC28 analogs that have phosphorothioate internucleotide linkages at various positions. The inhibitory effect depended on the total number of thioate linkages, rather than the position of the linkages within the oligomer or the chain length itself. No sequence specificity was found. In the presence of the complementary RNA, antisense phosphorothioates (S-oligos) exerted a biphasic effect on RNase H activity. At low concentrations S-oligos could enhance the cleavage of the RNA portion of S-oligo-RNA duplex, whereas at high concentrations (in excess of the complementary RNA) S-oligos could inhibit RNase H and protect the complementary RNA from degradation. Together, these results suggest that the non-sequence-specific inhibitory effect of S-oligos should be taken into consideration in designing antisense inhibitors. This inhibitory activity could be avoided by decreasing the number of phosphorothioate linkages at the backbone, and S-oligos of 15-20 residues are preferable in antisense molecule design.
硫代磷酸寡聚脱氧胞苷(S-dCn)被用作模型化合物,以研究硫代磷酸酯键的数量及其位置对体外抑制人DNA聚合酶和核糖核酸酶H的影响。链长超过15的S-dCn能够以键数依赖的方式抑制人DNA聚合酶和核糖核酸酶H的活性。较长的寡聚物比较短的寡聚物是更有效的抑制剂。动力学研究表明,S-dC28相对于DNA模板是DNA聚合酶α和β的竞争性抑制剂,而它是聚合酶γ和δ的非竞争性抑制剂。S-dC28相对于RNA-DNA双链体也是核糖核酸酶H1和H2的竞争性抑制剂。这些酶对S-dC28抑制的敏感性顺序为δ约γ大于α大于β,且核糖核酸酶H1大于核糖核酸酶H2。用一组在不同位置具有硫代磷酸酯核苷酸间键的S-dC28类似物探索了构效关系。抑制作用取决于硫代酸酯键的总数,而不是寡聚物内键的位置或链长本身。未发现序列特异性。在存在互补RNA的情况下,反义硫代磷酸酯(S-寡核苷酸)对核糖核酸酶H活性产生双相作用。在低浓度下,S-寡核苷酸可增强S-寡核苷酸-RNA双链体RNA部分的切割,而在高浓度下(超过互补RNA),S-寡核苷酸可抑制核糖核酸酶H并保护互补RNA不被降解。总之,这些结果表明,在设计反义抑制剂时应考虑S-寡核苷酸的非序列特异性抑制作用。通过减少主链上硫代磷酸酯键的数量可以避免这种抑制活性,并且在反义分子设计中15 - 20个残基的S-寡核苷酸是优选的。